BIOMAT Database Logo BIOMAT Database Logo

Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates. 1992

N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K.

Cholinergic replacement therapy for Alzheimer's disease using existing cholinesterase inhibitors is compromised by short duration, meagre benefits restricted to subgroups of patients, and peripheral toxicity. Heptyl physostigmine is a lipophilic carbamate derivative of physostigmine. In rhesus monkeys, heptyl physostigmine (0.2-0.9 mg/kg i.m.) fully reversed a scopolamine-induced cognitive impairment. Following oral administration in squirrel monkeys, heptyl physostigmine (8 mg/kg) induced long-lasting hypothermia (greater than or equal to 4 h), a centrally-mediated cholinergic effect. Erythrocyte acetylcholinesterase activity was inhibited by 86% at the time of peak hypothermia (180 min). Clinical trials with heptyl physostigmine will enable a more rigorous evaluation of cholinomimetic therapy for dementia.

UI MeSH Term Description Entries
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008297 Male Males
D008568 Memory Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory.
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001833 Body Temperature Regulation The processes of heating and cooling that an organism uses to control its temperature. Heat Loss,Thermoregulation,Regulation, Body Temperature,Temperature Regulation, Body,Body Temperature Regulations,Heat Losses,Loss, Heat,Losses, Heat,Regulations, Body Temperature,Temperature Regulations, Body,Thermoregulations
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004910 Erythrocyte Membrane The semi-permeable outer structure of a red blood cell. It is known as a red cell 'ghost' after HEMOLYSIS. Erythrocyte Ghost,Red Cell Cytoskeleton,Red Cell Ghost,Erythrocyte Cytoskeleton,Cytoskeleton, Erythrocyte,Cytoskeleton, Red Cell,Erythrocyte Cytoskeletons,Erythrocyte Ghosts,Erythrocyte Membranes,Ghost, Erythrocyte,Ghost, Red Cell,Membrane, Erythrocyte,Red Cell Cytoskeletons,Red Cell Ghosts

Related Publications

N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
September 1992, Neuroscience letters,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
Microbial transformation of N-heptyl physostigmine, a semisynthetic alkaloid inhibitor of cholinesterase.
August 1995, Journal of industrial microbiology,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.
August 1991, Pharmacology, biochemistry, and behavior,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
October 1989, Neurochemical research,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.
March 1987, Pharmacology, biochemistry, and behavior,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
A biomarker study in long-lasting amnestic mild cognitive impairment.
April 2018, Alzheimer's research & therapy,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
Odor Identification Impairment and Change with Cholinesterase Inhibitor Treatment in Mild Cognitive Impairment.
January 2020, Journal of Alzheimer's disease : JAD,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
Diazepam reversal by physostigmine.
October 1980, Anesthesia and analgesia,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
Hippocampal infusions of apolipoprotein E peptides induce long-lasting cognitive impairment.
April 2009, Brain research bulletin,
N M Rupniak, and S J Tye, and C Brazell, and A Heald, and S D Iversen, and P G Pagella
Cholinesterase inhibitors in vascular cognitive impairment.
July 2013, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Copied contents to your clipboard!